Core Viewpoint - LeXin Medical has a diverse range of health monitoring products, which are the main sources of revenue for the company [2] Product Line Summary - The company offers a variety of health monitoring products including smart electronic blood pressure monitors, electronic health scales, smart blood glucose monitoring products, body fat measurement devices, ECG monitoring equipment, and wearable devices such as bands and watches [2] - Recently launched products like OTC hearing aids and twelve-lead smart ECG shirts are gradually achieving commercial viability, although the company cannot yet predict their future impact on performance [2] - The medical-grade smart ring is currently under preparation and optimization, with features that include cardiovascular monitoring and assessment, in addition to basic monitoring functions like blood oxygen, sleep, heart rate, and exercise [2] - The smart ring is designed to be more portable and comfortable compared to existing watches and bands [2] - The company previously launched a medical-grade ECG watch, Lifesense Health Watch H1, but has not released the H2 model [2]

Core Viewpoint - The company is actively engaging with investors regarding its core products and their production status, highlighting the gradual commercialization of new products while emphasizing the ongoing development of its medical-grade smart ring. Group 1: Product Status - The company's core products include the iSENSE series twelve-lead smart ECG shirt, Nova OTC hearing aids, medical-grade smart ring, and LIFESENSE H2 ECG health watch, with the latter two still in the preparation phase and not yet officially launched [1] - The OTC hearing aids and twelve-lead smart ECG shirt are gradually achieving commercial rollout, although the company cannot yet predict their future impact on performance [1] Group 2: Product Features - The medical-grade smart ring is designed to offer additional monitoring and assessment of cardiovascular status, alongside basic functions such as blood oxygen, sleep, heart rate, and exercise tracking, making it more portable and comfortable compared to existing health watches and bands [1] - The company previously launched the medical-grade ECG watch LIFESENSE Health Watch H1 in 2019, but has not yet released the H2 model [1]

Investment Rating - The report maintains a rating of "Accumulate" for the company [4]. Core Views - The strategic transformation of the company is showing significant results, with the AI+ healthcare model expected to reshape the valuation system [2][3]. - The company has focused on high-margin medical-grade remote health monitoring devices and services, leading to improved operational efficiency and profitability [2]. - The company is well-positioned to benefit from the expansion of the chronic disease management market and the emerging AI+ healthcare sector [8]. Financial Summary - Revenue projections for 2024-2026 are estimated at 1.013 billion, 1.266 billion, and 1.585 billion yuan, respectively, with year-over-year growth rates of 14.5%, 25.0%, and 25.2% [1][8]. - The net profit attributable to the parent company is expected to reach 64 million, 105 million, and 145 million yuan for the same period, reflecting year-over-year growth rates of 85.5%, 64.6%, and 38.2% [1][8]. - The company's return on equity (ROE) is projected to improve from 5.5% in 2024 to 10.9% in 2026 [1]. Business Segments - The health equipment segment is focusing on new product launches, including blood glucose meters and hearing aids, which are expected to gain market traction [2]. - The RPM (Remote Patient Monitoring) segment has established deep collaborations with leading clients in Europe and the US, creating a closed-loop business model [2]. - The cardiovascular digital chronic disease service segment is integrating remote health monitoring devices with AI software and medical services, with initial validation in various healthcare settings [2]. Market Position and Future Outlook - The company has accumulated a substantial amount of multi-dimensional physiological data from over ten million users, laying a solid foundation for developing a vertical AI model in the cardiovascular field [3]. - The report anticipates that the company will achieve a revenue of 1.013 billion yuan in 2024, with a corresponding net profit of 0.64 billion yuan, indicating a strong growth trajectory [8].